Assessing Novavax (NVAX) Valuation After Pfizer Licensing Deal For Matrix M Adjuvant

Simply Wall St.06:27

Novavax (NVAX) is back in focus after a non exclusive licensing deal with Pfizer. The agreement gives Pfizer access to the Matrix M adjuvant for up to two infectious disease areas, with upfront cash, ...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment